Edition:
United Kingdom

Idorsia Ltd (IDIA.S)

IDIA.S on Swiss Exchange

25.74CHF
18 Jul 2018
Change (% chg)

CHF-0.44 (-1.68%)
Prev Close
CHF26.18
Open
CHF26.40
Day's High
CHF26.42
Day's Low
CHF25.50
Volume
410,149
Avg. Vol
319,321
52-wk High
CHF30.70
52-wk Low
CHF16.05

Chart for

About

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including... (more)

Overall

Beta: --
Market Cap(Mil.): CHF2,096.57
Shares Outstanding(Mil.): 119.12
Dividend: --
Yield (%): --

Financials

  IDIA.S Industry Sector
P/E (TTM): -- 85.36 32.76
EPS (TTM): -- -- --
ROI: -- 2.21 14.61
ROE: -- 3.85 16.34

UPDATE 1-Idorsia CEO accelerates fundraising with 505 mln Sfr deal

ZURICH, July 11 Swiss drugmaker Idorsia's Chief Executive Jean-Paul Clozel on Wednesday accelerated fundraising for his drug pipeline, reaping around 505 million Swiss francs ($509 million) by selling new shares and convertible bonds.

11 Jul 2018

Idorsia raises 505 mln Sfr from shares, bonds to fund pipeline

ZURICH, July 11 Swiss drugmaker Idorsia's Chief Executive Jean-Paul Clozel on Wednesday accelerated fundraising for his drug pipeline, reaping around 505 million Swiss francs ($509 million) by selling new shares and convertible bonds.

11 Jul 2018

BRIEF-Idorsia Launches Offering Of New Shares And Convertible Bonds

* IDORSIA LAUNCHES THE OFFERING OF NEW SHARES IN COMBINATION WITH THE OFFERING OF CONVERTIBLE BONDS TO FUND THE DEVELOPMENT OF ITS ADVANCING PIPELINE

10 Jul 2018

After split from Actelion, Idorsia CEO plans to raise more cash in 2019

ALLSCHWIL, Switzerland Swiss biotech Idorsia , spun off from Actelion last June with a $1 billion investment from buyer Johnson & Johnson , will seek fresh funding in 2019 to support late-stage trials of drugs getting underway, its CEO told Reuters.

18 Jun 2018

BRIEF-Idorsia Initiates Phase 3 Registration Program With Nemorexant For Treatment Of Insomnia

* INITIATES A PHASE 3 REGISTRATION PROGRAM WITH NEMOREXANT (ACT-541468) FOR TREATMENT OF INSOMNIA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

11 Jun 2018

BRIEF-Idorsia Starts Phase 3 Registration Study To Assess Lucerastat As Potential New Treatment Option For Patients With Fabry Disease

* IDORSIA INITIATES MODIFY, A PHASE 3 REGISTRATION STUDY TO ASSESS LUCERASTAT AS A POTENTIAL NEW TREATMENT OPTION FOR PATIENTS WITH FABRY DISEASE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

16 May 2018

BRIEF-Idorsia: US GAAP Oper Loss Of CHF 74 Mln In Q1 2018

* IDORSIA ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER 2018

19 Apr 2018

BRIEF-Idorsia FY US GAAP Loss Of CHF 8 Million

* US GAAP OPERATING RESULTS 2017: YTD LOSS OF CHF 8 MILLION; Q4 PROFIT OF CHF 71 MILLION

06 Feb 2018

Earnings vs. Estimates